| AASLD

Immune‐Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat

Read more about Immune‐Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat

Paul Martin – 9 April 2019

Physicians’ Perspectives on Palliative Care for Patients With End‐Stage Liver Disease: A National Survey Study

Read more about Physicians’ Perspectives on Palliative Care for Patients With End‐Stage Liver Disease: A National Survey Study

Nneka N. Ufere, John Donlan, Lauren Waldman, Arpan Patel, Jules L. Dienstag, Lawrence S. Friedman, Kathleen E. Corey, Nikroo Hashemi, Peter Carolan, Alan C. Mullen, Michael Thiim, Irun Bhan, Ryan Nipp, Joseph Greer, Jennifer Temel, Raymond T. Chung, Areej El‐Jawahri – 9 April 2019 – Specialty palliative care (PC) is underused for patients with end‐stage liver disease (ESLD). We sought to examine attitudes of hepatologists and gastroenterologists about PC for patients with ESLD. We conducted a cross‐sectional survey of these specialists who provide care to patients with ESLD.

Reply

Read more about Reply

Xin Chen, Satdarshan P. Monga, Diego F. Calvisi – 8 April 2019

Reply

Read more about Reply

Mayank Sharma, Siddharth Singh, Douglas A. Simonetto – 8 April 2019

Letter to the Editor: Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis

Read more about Letter to the Editor: Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis

Yu‐Jen Chen, Chia‐Fen Tsai, Yen‐Po Wang, Ching‐Liang Lu – 8 April 2019

Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol‐Inducible Cytochrome P450‐2E1–Mediated Oxidative and Nitrative Stress

Read more about Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol‐Inducible Cytochrome P450‐2E1–Mediated Oxidative and Nitrative Stress

Young‐Eun Cho, Do‐Kyun Kim, Wonhyo Seo, Bin Gao, Seong‐Ho Yoo, Byoung‐Joon Song – 8 April 2019 – Fructose intake is known to induce obesity, insulin resistance, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the effects of fructose drinking on gut leakiness, endotoxemia, and NAFLD and study the underlying mechanisms in rats, mice, and T84 colon cells.